WO2007034207A3 - Troventol formulation - Google Patents

Troventol formulation Download PDF

Info

Publication number
WO2007034207A3
WO2007034207A3 PCT/GB2006/003538 GB2006003538W WO2007034207A3 WO 2007034207 A3 WO2007034207 A3 WO 2007034207A3 GB 2006003538 W GB2006003538 W GB 2006003538W WO 2007034207 A3 WO2007034207 A3 WO 2007034207A3
Authority
WO
WIPO (PCT)
Prior art keywords
troventol
formulation
agents
640mcg
bronchospasms
Prior art date
Application number
PCT/GB2006/003538
Other languages
French (fr)
Other versions
WO2007034207A2 (en
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Turner Craig Robert
Amar Lulla
Geena Malhotra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd, Turner Craig Robert, Amar Lulla, Geena Malhotra filed Critical Cipla Ltd
Publication of WO2007034207A2 publication Critical patent/WO2007034207A2/en
Publication of WO2007034207A3 publication Critical patent/WO2007034207A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An aerosol composition suitable for use in the treatment of bronchospasms and related disorders comprises a therapeutically effective amount of troventol either alone or in combination with one or more suitable therapeutic agents and one or more pharmaceutically acceptable carriers. The composition preferably contains 40-640mcg of troventol and may comprise a carrier chosen from one or more of propellants, cosolvents, antioxidants, surfactants, surface active agents, and bulking agents.
PCT/GB2006/003538 2005-09-25 2006-09-25 Troventol formulation WO2007034207A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN884/MUM/2005 2005-09-25
IN884MU2005 2005-09-25

Publications (2)

Publication Number Publication Date
WO2007034207A2 WO2007034207A2 (en) 2007-03-29
WO2007034207A3 true WO2007034207A3 (en) 2007-07-12

Family

ID=37450755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003538 WO2007034207A2 (en) 2005-09-25 2006-09-25 Troventol formulation

Country Status (2)

Country Link
RU (1) RU2457832C2 (en)
WO (1) WO2007034207A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147154A1 (en) * 2018-01-23 2019-08-01 Александр Григорьевич ЧУЧАЛИН Pharmaceutical formulation (embodiments) and use of a pharmaceutical formulation (embodiments)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955058A (en) * 1992-12-09 1999-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations containing ipratropium bromide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955058A (en) * 1992-12-09 1999-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations containing ipratropium bromide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GORIACHKINA L A ET AL: "[Troventol treatment of patients with bronchial asthma and obstructive bronchitis]", VRACHEBNOE DELO AUG 1989, no. 8, August 1989 (1989-08-01), pages 40 - 41, XP008078589, ISSN: 0049-6804 *
NAYAK V G ET AL: "Quantitative determination of troventol from aerosols by reversed phase liquid chromatography", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 1994 UNITED STATES, vol. 20, no. 8, 1994, pages 1485 - 1491, XP008078588, ISSN: 0363-9045 *

Also Published As

Publication number Publication date
WO2007034207A2 (en) 2007-03-29
RU2008115918A (en) 2009-10-27
RU2457832C2 (en) 2012-08-10

Similar Documents

Publication Publication Date Title
WO2005007142A3 (en) Liquid compositions comprising formoterol
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2004113335A3 (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
WO2004021968A3 (en) Solution for ungual application
WO2006048747A8 (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2006058007A3 (en) Jnk inhibitors for treatment of cns injury
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
WO2004006859A3 (en) Platinum compound
WO2003065992A3 (en) Treating benign prostate hyperplasia with sarms
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
WO2002089791A3 (en) Acne treatment with lipooxigenase inhibitors
WO2005112633A3 (en) Compounds and compositions for delivering active agents
AU2003240949A1 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2006004703A3 (en) PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
WO2006007312A3 (en) Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2002004409A3 (en) Tetrahydrobenzothiazole analogues as neuroprotective agents
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 740/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008115918

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06779535

Country of ref document: EP

Kind code of ref document: A2